Plain-English translation of NCT07582432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing Gamunex-C, an intravenous immune treatment given once a month, to see if it helps prevent serious infections in people with certain blood cancers. People with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma often have weakened immune systems that make them vulnerable to infections. The study will check whether this medication, combined with standard cancer care, can reduce how often and how severely these infections occur.
People diagnosed with these blood cancers often develop weak immune systems that cannot fight off infections well. This medication aims to boost the body's infection-fighting abilities, but doctors need to confirm it truly works and is safe for this specific group of patients.
You likely qualify if…
You likely don't qualify if…
You would come to a medical center approximately once every 4 weeks for one year to receive an intravenous infusion of the medication — a total of 13 doses. You will continue your regular cancer treatment during this time. The study team will monitor you for infections, check your blood work, and track how well the medication is working and any side effects you experience.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States